Tools to help you put the guidance into practice.

NICE is unable to make a recommendation about the use in the NHS lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in adults. This is because Celgene ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

There is a simple discount patient access scheme for QuiremSpheres. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

the hepatocellular carcinoma cannot be removed by surgery (unresectable), and they have Child‑Pugh grade A liver impairment and conventional therapies given through an artery (transarterial) are not ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

Tools to help you put the guidance into practice.

This recommendation is not intended to affect treatment with QuiremSpheres that was started in the NHS before this guidance was published. People having treatment outside this recommendation may ...

QuiremSpheres (Terumo) received its CE mark in April 2015. It is classified as an Active Implantable Medical Device by Council Regulation (EU2017/745). It is indicated for treating unresectable liver ...

NICE has recommended the selective internal radiation therapy (SIRT) QuiremSpheres as an option for treating unresectable advanced hepatocellular carcinoma (HCC) in adults, only if it is: used for ...